Toulouse, February 21st, 2017 (8:00AM CET) – VEXIM (FR0011072602 – ALVXM), a medical device company specializing in the minimally-invasive treatment of vertebral fractures, today announces enrollment completion of its FDA clinical trial. The VEXIM FDA trial is a European, prospective and randomized multicenter study. It aims to compare safety and […]